Target Name: CD300LB
NCBI ID: G124599
Review Report on CD300LB Target / Biomarker Content of Review Report on CD300LB Target / Biomarker
CD300LB
Other Name(s): CD300 molecule like family member b | CLM-7 | IREM-3 | TREM5 | LMIR5 | CLM7_HUMAN | Leukocyte mono-Ig-like receptor 5 | triggering receptor expressed on myeloid cells 5 | leukocyte mono-Ig-like receptor 5 | CLM7 | Immune receptor expressed on myeloid cells 3 | CMRF35-A2 | IREM3 | CMRF35A2 | immune receptor expressed on myeloid cells 3 | CD300 antigen like family member B | TREM-5 | Triggering receptor expressed on myeloid cells 5 | CD300b | CMRF35-like molecule 7 | CD300 antigen-like family member B | OTTHUMP00000070873

CD300LB: A Potential Drug Target and Biomarker

The CD300 family is a family of cytokines that play a crucial role in the regulation of immune responses and inflammation. CD300LB, a member of the CD300 family, has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders , and neurodegenerative diseases.

CD300LB is a glycoprotein that consists of a single constant region and a variable region. The variable region of CD300LB contains a unique domain that is involved in its ability to interact with various cytokines and chemokines, allowing it to play a critical role in the regulation of immune responses and inflammation.

CD300LB has been shown to be involved in the regulation of T cell development and function. T cells are a crucial immune cell that play a vital role in protecting the body against infection and disease. CD300LB has been shown to regulate the development and differentiation of T cells, as well as the regulation of their functions, such as T cell proliferation and activation.

In addition to its role in T cell regulation, CD300LB has also been shown to be involved in the regulation of inflammation. Inflammation is a critical immune response that helps the body to fight off infection and disease. CD300LB has been shown to regulate the production and function of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾, which are crucial for the regulation of inflammation.

CD300LB has also been shown to be involved in the regulation of cancer progression. Cancer is a leading cause of death worldwide, and its progression is a complex process that is influenced by numerous factors. cell growth, angiogenesis, and the development of cancer stem cells.

In addition to its role in cancer, CD300LB has also been shown to be involved in the regulation of autoimmune disorders. Autoimmune disorders are a group of diseases that result from an abnormal immune response, leading to inflammation and damage to the body's tissues. CD300LB has has been shown to be involved in the regulation of the development and function of autoimmune T cells, which are crucial for the regulation of autoimmune disorders.

CD300LB has also been shown to be involved in the regulation of neurodegenerative diseases. Neurodegenerative diseases are a group of diseases that result from the progressive loss of neural cells and their functions, leading to the development of various neurological symptoms. involved in the regulation of the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, CD300LB is a molecule like family member b that has been shown to be involved in the regulation of immune responses, inflammation, cancer, autoimmune disorders, and neurodegenerative diseases. As a potential drug target and biomarker, CD300LB is a promising target for the development of new therapies for these diseases. Further research is needed to fully understand the role of CD300LB in the regulation of immune responses and disease, and to develop effective treatments.

Protein Name: CD300 Molecule Like Family Member B

Functions: Acts as an activating immune receptor through its interaction with ITAM-bearing adapter TYROBP, and also independently by recruitment of GRB2

The "CD300LB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD300LB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4